ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-mesothelin Antibody-drug Conjugate SGN-MesoC2

In Pfizer’s pipeline, mesothelin-targeted antibody-drug conjugate. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Pfizer.

Furthest: phase 1, since Jun 11, 20241 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer10 open or runningphase 1since Jun 11, 2024Jun 11, 2024none ahead
  • Named in Pfizer’s own pipeline as PF-08052666, phase 1, as of Nov 3, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 11, 2024First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06466187 · 19 enrolled · United States, Canada

TargetBeta

“mesothelin-targeted antibody-drug conjugate”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a human monoclonal antibody directed against the cell surface glycoprotein and tumor-associated antigen (TAA) mesothelin (MSLN) and conjugated, via a tumor-specific cleavable linker, to a topoisomerase-1 inhibitor (TOP1i), with potential antineoplastic…”NCIt, read by Claude

Other programs on MSLN

ProgramCompanyFurthest phaseStudies
Autologous IL-2-expressing Anti-mesothelin CAR T-cells OPB-101ruleoutpace-bio-incphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06466187Carcinoma, Non-Small-Cell Lung · United States, Canada1TerminatedMay 27, 202619

How it is read

Names in the registry

  • “PF-08052666”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.